hr

Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Top
Hepatoma Res 2021;7:[Accepted].10.20517/2394-5079.2021.84@The Author(s) 2021
Accepted Manuscript
Open AccessPerspective

Neoadjuvant and adjuvant systemic treatment for hepatocellular carcinoma


Correspondence Address: Dr. Leonardo G. da Fonseca, São Paulo Clínicas Liver Cancer Group – Hospital das Clínicas Complex, Instituto do Cancer do Estado de São Paulo, University of São Paulo School of Medicine. Av Dr. Arnaldo, 450, São Paulo, Brazil. E-mail: l.fonseca@fm.usp.br

...

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Abstract

Hepatocellular carcinoma (HCC) is a highly lethal malignancy and few patients are candidates for curative-intended therapies. The mainstay of curative treatment in HCC is surgical resection, ablation, and transplantation. However, rates of recurrence are high and there is no established approach to reduce the risk of recurrence and mortality. We discuss the available data and current landscape of (neo) adjuvant therapies aimed at decreasing recurrence risk and improving overall survival, including liver-directed therapies, tyrosine kinase inhibitors and immunotherapy. Neoadjuvant strategies aimed at downstaging advanced HCC to enable local treatment and minimize the risk of recurrence using novel agents are also a topic of interest in current research. The improvements achieved in the advanced stages with immune-checkpoint inhibitors are priming ongoing trials that address potential future directions for both adjuvant and neoadjuvant strategies that may change the treatment paradigm of HCC in the near future.

Cite This Article

Mathias-Machado MC, da Fonseca LG. Neoadjuvant and adjuvant systemic treatment for hepatocellular carcinoma. Hepatoma Res 2021;7:[Accept]. http://dx.doi.org/10.20517/2394-5079.2021.84

© 2016-2021 OAE Publishing Inc., except certain content provided by third parties